Position in RPRX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$333,672
+$60,291 QoQ
Shares Held
5,951
+4.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#447
of 641 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Csenge Advisory Group holds $2,906,060 across 6 Biotechnology names. RPRX ranks #4 (11.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
5,037 | $1,213,765 | |
| 2 | ASND |
Ascendis Pharma A/S
|
2,171 | $579,049 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
2,067 | $505,939 | |
| 4 | RPRX |
Royalty Pharma plc
This page
|
5,951 | $333,672 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
511 | $253,829 | |
| 6 | GERN |
Geron Corp
|
15,474 | $19,806 |
All Filings in RPRX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $333,672 | 5,951 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $273,381 | 5,699 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $227,241 | 5,881 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $215,666 | 6,113 | Shares | Sole | 2025-10-28 | |
| No filing history on record for this holder in this stock. | ||||||